Overview of Tadalafil Tablets
Dosage StrengthCommercial (Cialis®): 2.5 mg, 5 mg, 10 mg, 20 mg
Commercial (Generic): 2.5 mg, 5 mg, 10 mg, 20 mg
Similar to sildenafil and vardenafil, tadalafil is a selective phosphodiesterase (PDE) type 5 inhibitor. Male erectile dysfunction (ED), pulmonary arterial hypertension (PAH), benign prostatic hypertrophy (BPH), or the simultaneous therapy of ED and BPH, are all treated with it orally. Tadalafil does not suppress prostaglandins like some impotence medications do (e.g., alprostadil). Tadalafil, which is more selective for PDE5 than for PDE6 found in the retina and differs from sildenafil in that it has not been linked to reports of visual abnormalities. Tadalafil appears to have a longer half-life of effect (up to 36 hours) than sildenafil and vardenafil for the treatment of ED. Since erections are only induced by PDE inhibitors when there is sexual stimulation, tadalafil’s extended half-life permits more spontaneity in sexual engagement. Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitor) are regarded as first-line therapy for treating ED. 1 Phase II trials for the treatment of female erectile dysfunction with tadalafil were conducted, however further research was halted. Male erectile dysfunction (ED) medication received FDA approval in November 2003, and once-daily use without respect to sexual activity time received FDA approval in January 2008. In May 2009, the FDA approved tadalafil (Adcirca) for the treatment of pulmonary arterial hypertension (PAH). Tadalafil-treated patients in clinical studies of patients with pulmonary arterial hypertension (PAH) had greater exercise capacity and less clinical deterioration compared to placebo-treated patients. Tadalafil obtained FDA approval in October 2011 for the management of benign prostatic hyperplasia (BPH) signs and symptoms as well as the co-management of erectile dysfunction and BPH.
1.Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2.Cialis (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2011 Oct.
3.Adcirca (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2011 Apr.
4.Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin N Am 2007;34:631-642.
5.Bortolotti M, Mari C, Giovannini M, et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci 2001;46:2301-2306.
6.Cialis® (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2007 Jan.
7.Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014 May.
8.Intelence (etravirine) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Aug.
9.Mifeprex (mifepristone, RU-486) package insert. New York, NY: Danco Laboratories, LLC; 2009 Apr.
10.Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics Incorporated; 2013 Jun.
11.Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
12.Tasigna® (nilotinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007 Oct.
13.Kuvan (sapropterin) package insert. Novato, CA: BioMarin Pharmaceutical Inc; 2014 April.
14.Adalat CC (nifedipine extended-release tablets) package insert. West Haven, CT: Bayer Pharmaceuticals Corporation; 2010 Aug.
15.Levitra® (vardenafil) package insert. Kenilworth, NJ: Schering-Plough; 2007 Mar.
16.Ketek (telithromycin) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals; 2010 Dec.
17.Incivek (telaprevir) tablet package insert. Cambridge, MA: Vertex Pharmaceuticals, Inc; 2013 Oct.
18.Padma-Nathan H, McMurray JG, Pullman WE, et al. On-demand IC351 (Tadalafil) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2-9.
19.Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005;25:9-13.
20.Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol 2005;123(3):399-400.
21.Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005;123(3):400-1.
22.Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye 2005;19(6):715-7.
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.